Leukemia
News
Treanda® Included in NCCN Guidelines for CLL and NHL
(05/05/2008)
The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
Genetic Differences Associated with Outcomes in Acute Myeloid Leukemia
(05/01/2008)
It appears that different genetic mutations (alterations) affect outcomes among patients with acute myeloid leukemia. These results were recently published in the New England Journal of Medicine.
FDA Approves Treanda® for Initial Treatment of Chronic Lymphocytic Leukemia
(04/25/2008)
The U.S. Food and Drug Administration has recently approved the drug Treanda® (bendamustine) for the treatment of chronic lymphocytic leukemia (CLL). The approval is based on data indicating that, for patients with CLL, Treanda improved overall response and complete response rates as well as progression-free survival rates compared with the commonly used agent chlorambucil.
Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis
(03/10/2008)
A large study conducted in Canada reveals that patients who are treated for rheumatoid arthritis (RA) with the drug cyclophosphamide may have an increased risk for developing hematological cancers such as lymphoma.
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
More
Leukemia
Cancer News...